Background The appropriate duration of dual antiplatelet therapy in patients at high risk for
bleeding after the implantation of a drug-eluting coronary stent remains unclear. Methods …

Background The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous
coronary intervention (PCI) among patients at high bleeding risk (HBR) is unknown …

Background—The optimal duration of dual-antiplatelet therapy and the risk-benefit ratio for
long-term dual-antiplatelet therapy after coronary stenting remain poorly defined. We …

Aim To assess the effects of 1-or≥ 3-month dual antiplatelet therapy (DAPT) in high
bleeding risk (HBR) patients who received biodegradable-polymer sirolimus-eluting stents …

Background Dual antiplatelet therapy is recommended after coronary stenting to prevent
thrombotic complications, yet the benefits and risks of treatment beyond 1 year are …

BACKGROUND: The optimal duration of dual antiplatelet therapy after percutaneous
coronary intervention (PCI) is unknown. Incremental reductions in the risk of major adverse …

Background: Despite treatment guidance endorsing shortened dual antiplatelet therapy
(DAPT) duration in high bleeding risk (HBR) patients after drug-eluting stents, limited …

Objectives: The purpose of this study was to evaluate the safety of dual antiplatelet therapy
in patients in whom long-term anticoagulation (AC) with warfarin is recommended …

Importance Very short mandatory dual antiplatelet therapy (DAPT) after percutaneous
coronary intervention (PCI) with a drug-eluting stent may be an attractive option. Objective …

Background: Although some randomized controlled trials (RCTs) and meta-analyses have
suggested that prolonged dual-antiplatelet therapy (DAPT) may be associated with …